In a patient with recurrent grade IV glioma of the brain resistant to conventional treatment an antibody guided isotopic scan showed uptake by the tumour of a monoclonal antibody (9A) that was developed against epidermal growth factor receptor but cross reacted with
and carbon monoxide inhaled by people smoking low tar cigarettes can be higher than the yields measured by standard laboratory methods'3-'5 as machines do not smoke cigarettes in the same manner as people. 13 Hence the real exposure to tar of the smokers of low tar cigarettes in this study may have been close to that of the smokers of medium tar cigarettes, which may account for the similar prevalence of symptoms between these two groups.
The decline in the yield of tar in cigarettes has contributed to the reduced risk of cancer of the lung and chronic obstructive pulmonary disease among smokers until recent years. 16 Unfortunately, we have to wait for many years before the effects on health of new low tar brands of cigarettes can be shown in epidemiological studies using these diseases as an outcome. Many important differences in physical properties of new low tar cigarettes exist compared with the older ones, and therefore the conclusion referred to above cannot be interpreted as evidence that health hazards will diminish as a function of a yield of tar below 10 mg. On the contrary, our data and some other recent epidemiological7-9 and experimentall7 studies have not shown any significant differences in the effects on health of low tar brands compared with the medium tar brands. Although we cannot draw conclusions on the risk of cancer of the lung or obstructive pulmonary diseases on the basis of these studies, the medical evidence available does not support the hypothesis that cigarettes yielding less than 10 mg tar are safer than those yielding 10-18 mg.
Introduction
Grade IV glioma is one of the most rapidly fatal neoplasms, with a median survival of 14 weeks after biopsy.' Postoperative radiotherapy extends survival and improves quality of life in most cases.2 The remission, however, is usually short lived and the long term survival rate negligible. Some evidence exists that the length of survival can be increased by giving higher doses of radiation. Salazar et al reported a small series of cases in which doses of 7500 cGy (7 5 rads) were given to the tumour with apparent improvement in survival.3 High biological doses using fast neutrons have been shown to achieve tumour sterilisation but at the expense of unacceptable brain damage. 4 It is theoretically possible that antibody guided irradiation could deliver a tumoricidal dose with a minimal dose to normal brain tissue. Antibody guided irradiation of malignant lesions has been attempted in the past with only limited success,5 6 but we have recently reported that the regional rather than systemic infusion of radioactively labelled tumour associated monoclonal antibodies can produce encouraging results in the treatment of some malignant diseases such as ovarian cancer.7 This is probably because regional administration can produce higher uptake by the tumour and lower uptake by normal tissue of a radiolabelled antibody than can systemic administration.
We chose antibody 9A, which was originally produced against epidermal growth factor receptor but was subsequently found to cross react with blood group A antigen. On previous immunochemical tests Phase 2 This refers to the therapeutic delivery of radioactively labelled antibody by internal carotid artery infusion. Scans of head and total body were also taken after administration of labelled antibody to calculate the delivered dosage of radiation.
Dosimetry
For treatment to be effective the dose of radiation to the target should be high relative to the whole body or other sensitive organs. To calculate these doses it is necessary to know the proportion of the administered activity going to the target and to other relevant organs, the time course of the activity in the target and through the body, and the volume of distribution of the activity in the target. Volumes for the major organs of the body have been tabulated for "reference man" and may be assumed to be sufficiently accurate for most calculations of dosage.
Each of these factors can be found only approximately, and errors in the final dosimetry calculations are to be expected. Uptakes in the various parts of the body are assessed by quantitative imaging aided by blood activity disappearance curves. Conventional imaging of the body does not usually take into account the varying attenuation of the emitted radiation and the varying response of the detector over different sites, so that the picture of count rates that is obtained reflects only the distribution of activity. Scintillation cameras and rectilinear scanners can, however, be calibrated using phantoms and deriving attenuation factors to give results in millicuries. Sequential conventional imaging under the same conditions with recording of the results using a computer system allows a time activity curve to be obtained from any region of interest in the body. When the source is sufficiently well localised the disappearance of activity can be monitored with a collimated probe counter viewing the same site over several successive days.
Assessing the volume over which the activity in the tumour is distributed is difficult. Tomographic imaging is necessary for a full three dimensional description of the volume, and, although x ray computed tomography has been employed, the anatomy described may not correspond to the functioning tissues taking up the activity.
Isotope tomography often has too low a resolution for the small volumes encountered. Thus often only an approximate estimate of volume based on a projected area combined with an assumed thickness is available. In the case of, say, a pleural cavity the unknown thickness may vary from millimetres to centimetres and the final dosimetry estimates will reflect this inaccuracy.
The mean dose absorbed to the target and other affected organs is obtained using the method of the Medical Internal Radiation Committee.'3 This dose is the product of the cumulated activity (in ,uCi hours) in the region and the summed products of all the equilibrium dose constants (in g rad/pCi hours) and specific absorbed fractions (in g--') for the emissions of the radionuclides used.
For this work a conventional camera, a rotating tomographic camera interfaced to a nuclear medicine computing system, and a quantitative whole body scanning camera with off line computing facilities have all been used at various stages to monitor and image the distributions of activity. A probe counter was also used to obtain time over activity curves for localised sources.
Results
Antibody 9A was radiolabelled to a specific activity of 185 MBq (5 mCi)/mg. Immunoassays did not show any loss of antibody reactivity after radiolabelling, and the patient did not show any allergic reactions to the injected antibody. Quality control tests showed the antibody to be sterile and apyrogenic.
Dosimetry calculations
A phase 1 study (fig 2) (intravenous route) showed that a dosage of 1665 MBq (45-0 mCi) "3I labelled antibody could deliver to the tumour (30 g mass as estimated by computed tomography) 55 Gy (5500 rads) and 130, 600, and 600mGy (13, 60, 60 rads) to the whole body, liver, and kidneys, respectively. It is recognised, however, that these results represent only a first order approximation to accurate microdosimetry. We calculated, however, that an arterial infusion of labelled antibody would deliver a higher tumour dosage than that obtained via the venous route and that this advantage would depend on factors influencing the time integrals of the arterial antibody concentrations obtained by arterial versus venous infusion respectively. The regional advantage would depend on the total body clearance of radiolabelled antibody, on the extraction ratio of antibody by the target, and, inversely, on the rate of antibody infusion through the regional artery.'4 Thus significantly-that is, greater than twofoldincreased exposure with carotid arterial infusion could be obtained.
(.) We used a monoclonal antibody that was originally thought to be against epidermal growth factor receptor but was subsequently found to react with blood group A antigen.
Epidermal growth factor receptors on A431 cells express the oligosaccharide detected by antibody A9 but it is not yet clear (work in progress) whether in other neoplasms such as gliomas this blood group A epitope is expressed as part of a truncated epidermal growth factor receptor or is expressed independently.
Gliomas and other brain tumours of non-neuronal origin express epidermal growth factor receptors,'5 and this expression may accompany the malignant transformation. '6 Blood group A and other blood group antigens have been shown to be expressed by some cancers. '7 In a patient such as this, with blood group 0, who has a tumour expressing blood group A antigen, the use of an antibody to blood group A offers the chance of a "tumour specific" antibody guided approach. 
